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Highlights 
• Palatable foods elicit striatal dopamine release to strongly influence feeding. 
• Obesity is associated with aberrant striatal dopamine signaling. 
• Imbalance in striatal dopamine signaling may promote post-dieting weight regain. 
• Surgery may correct striatal dopamine signaling to modify fat reward value. 
 
Highly palatable and/or calorically dense foods, such as those rich in fat, engage the striatum to 
govern and set complex behaviors. Striatal dopamine signaling has been implicated in hedonic 
feeding and the development of obesity. Dieting and bariatric surgery have markedly different 
outcomes on weight loss, yet how these interventions affect central homeostatic and food reward 
processing remains poorly understood. Here, we propose that dieting and gastric bypass produce 
distinct changes in peripheral factors with known roles in regulating energy homeostasis, 
resulting in differential modulation of nigrostriatal and mesolimbic dopaminergic reward 
circuits. Enhancement of intestinal fat metabolism after gastric bypass may also modify striatal 
dopamine signaling contributing to its unique long-term effects on feeding behavior and body 
weight in obese individuals. 
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Obesity and post-dieting weight regain 
The obesity pandemic continues to grow in industrialized and nonindustrialized nations alike, 
with recent estimates that as many as one-third of the world population is overweight or obese 
[1]. As one of the leading causes of morbidity and mortality, obesity poses a serious health and 
socioeconomic problem [2]. A central question that arises when attempting to understand obesity 
is why elevated fat mass once established is so resilient, as most individuals eventually regain 
weight lost by conventional means such as caloric restriction [3]. 
 
The reasons for weight regain seem to be twofold. First, the integrity of the homeostatic system 
is maintained in obesity and drives behavioral and physiological responses to return adipose 
tissue stores to the predieting (higher) steady state [4]. Second, energy-dense foods appear to 
become even more desirable following abstinence, and individuals most often relapse onto such 
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foods even in the absence of weight loss [5]. Consequently, postdieting weight regain constitutes 
one of the greatest challenges in dealing with the growing obese population today. Despite 
significant progress in our understanding of the neurobiology of energy homeostasis, little is 
known regarding how brain regions designed to promote weight stability are affected by 
overconsumption of high-energy foods and altered in diet-induced obesity (DIO). 
 
Bariatric surgical procedures such as Roux-en-Y gastric bypass (RYGB) and vertical sleeve 
gastrectomy (VSG) are presently the most efficacious treatments for obesity [6], causing 
significant and long-term weight loss. This unique outcome for RYGB at least appears to be 
driven by changes in homeostatic and nonhomeostatic food processing (Box 1), which together 
may result in a reduced sense of hunger [7], reduced desire to eat [7], and reduced motivation to 
obtain high-energy foods [8]. Understanding how bariatric surgery overcomes homeostatic 
adiposity defense and targets central hedonic processing may enable the development of more 
effective and less invasive anti-obesity therapies in the future. 
 
Box 1.  
Homeostatic and Hedonic Feeding 
The hypothalamus plays a fundamental role in the regulation of whole body energy homeostasis. 
Excess energy is stored as fat mass, which in turn controls caloric intake and energy expenditure 
[65]. A second superimposed system exists, sensitive to food that is being consumed, and this 
feedback system controls meal size and the sensation of satiety [65]. Although these different 
tonic and phasic control systems interact in complex ways, their overall integration in the 
hypothalamus is normally remarkably effective at maintaining relatively constant levels of 
adiposity. In contrast to what would be expected with such a robust homeostatic control system 
for energy balance, the world is in the midst of an obesity crisis. The problem seems to derive 
from how HF foods in particular can over-ride negative feedback signals acutely and then 
disrupt homeostatic signaling chronically. Following chronic consumption, an HFD causes a 
state of hypothalamic inflammation and resistance to peripheral adiposity signals leading to 
weight gain [66]. Therefore, it can be said that while a homeostatic system for maintaining 
constant energy balance is in place, it is vulnerable to attack and eventually shuts down in the 
face of a chronic HFD, leading to obesity. 
The effects of an HFD do not stop at the level of the hypothalamus, and homeostatic 
dysregulation is unlikely the sole determinant of the ongoing obesity issue in environments 
characterized by ubiquitous access to highly palatable, energy-rich foods. An important aspect 
thus is the hedonic properties of food, which lead to feeding when there is no nutritional need 
[5]. An anatomical substrate for a homeostatic–hedonic interaction for feeding derives from 
studies revealing that μ-opioid receptor activation in the ventral striatum drives consumption of 
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palatable HF food in otherwise sated rats by engaging a distributed network of regions within 
the hypothalamus [67]. The hypothalamus itself sends indirect projections to the ventral striatum 
to modulate hedonic feeding according to nutritional status [67]. Thus, there is considerable 
crosstalk between the homeostatic and hedonic systems, congruent with a highly integrated 
system governing food intake. Interestingly, transgenic mice with defective protein kinase A 
signaling in the striatum, are resistant to diet induced obesity (DIO) even in the face of an 
orexigenic neuropeptide profile in the hypothalamus. Despite having maintained preference for a 
HF diet, these mice consumed less than their wild type counterparts [68]. These results suggest 
that long-term regulation of striatal signaling can exert dominant effects on homeostatic and 
hedonic feeding and bodyweight. 
 
Role of brain dopamine in feeding and obesity 
Brain dopamine signaling is essential for the rewarding and reinforcing properties of artificial 
stimuli such as drugs of abuse and natural stimuli such as food, and impacts powerfully on goal-
directed and habitual behaviors [9]. Accumulating evidence suggests that the brain dopamine 
system regulates whole body energy homeostasis. Dopamine-lesioned and genetically dopamine-
deficient mice are profoundly aphagic 9 and 10, and feeding induces robust brain dopamine 
release [11]. Moreover, dopamine release is changed in various models of obesity including 
genetically obese mice [12] and obesity prone and DIO rats [13], as well as in obese humans 
[14]. These observations demonstrate both that aberrant brain dopaminergic transmission is 
associated with altered feeding behavior and that elevated fat mass is associated with aberrant 
brain dopaminergic transmission. It is therefore possible that restoration of normal brain 
dopamine function may effectively reverse detrimental feeding behavior and obesity. 
 
The main dopaminergic projections in the central nervous system (CNS) arise from the ventral 
tegmental area (VTA) and substantia nigra (SN) of the midbrain, and terminate largely in the 
ventral and dorsal striatum forming the mesolimbic and nigrostriatal pathways respectively 
(Figure 1). As well as being anatomically segregated, these pathways are functionally divided 
and act in parallel to govern distinct processes. While these pathways have been extensively 
investigated in the context of drug addiction and motor function respectively, roles in food intake 
regulation have been assigned [9] with a focus almost exclusively on the mesolimbic pathway 
(Box 2). A recent human neuroimaging study revealed that the ventral and dorsal striatum can be 
dissociated based on adiposity and hedonic feeding in relation to dopamine 2 receptor (D2R) 
availability [15]. We present further evidence arguing that the mesolimbic and nigrostriatal 
dopaminergic pathways can be functionally dissociated in the regulation of energy balance, 
analogous to the proopiomelanocortin (POMC) and agouti-related peptide (AgRP) neuronal 
systems of the hypothalamic arcuate nucleus (ARC). We elaborate on how ventral striatal 
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dopamine generally promotes feeding on energy-dense foods. We then present the novel and 
perhaps slightly more contentious concept that dorsal striatal dopamine performs the opposite 
function decreasing feeding of energy dense foods and actually promoting feeding of less energy 
dense foods specifically by modifying the reward value of fat. Lastly, we apply this model to 
changes in hedonic feeding following weight loss after dieting and bariatric surgery, and 
hypothesize on the underlying mechanisms of surgically induced weight loss maintenance, with 
a focus on modifications in gut–striatal dopamine signaling. 
 
 
Figure 1 Modulation of mesolimbic and nigrostriatal pathways. (A) This panel shows the 
differential modulation of mesolimbic and nigrostriatal pathways by peripheral regulators of 
energy balance. In the normal state, anorexigenic factors such as leptin 12, 69 and 70, GLP-1 21 
and 23, insulin 71 and 72, and amylin 57 and 58 act to decrease mesolimbic neuronal activity 
and/or ventral striatal dopamine release (−) to reduce hedonic feeding, while orexigenic factors 
such as ghrelin 16, 17 and 19 and corticosterone [33] perform the opposite function and act to 
increase mesolimbic neuronal activity and/or ventral striatal dopamine release (+) to promote 
hedonic feeding. OEA (and presumably also BHB) acting on vagal afferents arising from the gut 
[27] causes increased nigrostriatal neuronal activity and increased dorsal striatal dopamine 
release to reduce hedonic feeding. (B) A diet-induced obese state induces aberrant regulation of 
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mesolimbic and nigrostriatal pathways. Chronic consumption of an HFD results in leptin and 
insulin resistance [65]. This would be expected to increase mesolimbic tone (denoted by the 
strengthened projection), ventral striatal dopamine and hedonic feeding. Chronic consumption of 
an HFD also decreases OEA (and presumably also BHB) synthesis [59], resulting in decreased 
nigrostriatal tone (denoted by the weakened projection) [27], and dorsal striatal dopamine, and 
increased hedonic feeding. (C) Chronic caloric restriction causes dominant mesolimbic pathway 
signaling, leading to weight regain. Chronic caloric restriction results in a hyperghrelinemic 32 
and 33 and hypercorticosteronemic 33 and 48, state, which would be expected to increase 
mesolimbic tone, ventral striatal dopamine and hedonic feeding. (D) RYGB surgery causes 
dominant nigrostriatal pathway signaling leading to long-term weight loss. RYGB results in the 
unique combination of increased circulating GLP-1 46 and 47 and amylin 46 and 47, and low 
ghrelin 46 and 47 and corticosterone [48]. Leptin and insulin sensitivities would also be restored 
and in the case of leptin is crucial for weight loss maintenance after surgery [73]. Together, this 
would be expected to decrease mesolimbic tone, ventral striatal dopamine and hedonic feeding. 
Additionally, RYGB may also increase OEA (and possibly also BHB) increasing mesolimbic 
tone, dorsal striatal dopamine and decrease hedonic feeding. Abbreviations: BHB, β 
hydroxybutyrate; CPu, caudate-putamen; GLP, glucagon-like peptide; HFD, high-fat diet; NAc, 
nucleus accumbens; OEA, oleoylethanolamide; RYGB, Roux-en-Y gastric bypass; SN, 
substantia nigra; VTA, ventral tegmental area. 
 
Box 2.  
Mesolimbic dopamine signaling and hedonic feeding 
Studies in rodents have consistently shown that elevated levels of ventral striatal dopamine 
increase the motivation to consume food; particularly energy-dense food [67]. The reinforcing 
nature of ventral striatal dopamine signaling has two distinct effects on energy-dense food 
intake: an immediate effect on consumption and an enduring effect on behavior. These two 
processes influence each other such that the reduced reward in response to food ingestion due to 
dopamine receptor blockade on one day, results in diminished motivation to obtain that reward 
on a subsequent day [9]. Similarly, the ability of sucrose, but not non-nutritive sucralose, to 
cause animals to remember positions where it was consumed, is associated with its ability to 
elicit ventral striatal dopamine release [74]. Studies in drosophila have further revealed that 
appetitive long term memory (LTM) develops with D-glucose but not its non-nutritive (yet 
similarly sweet) enantiomer L-glucose via a post-ingestive mechanism. The ability of D-glucose 
to cause appetitive LTM is abolished with dopamine receptor inhibition while dopamine neuron 
stimulation is sufficient to induce appetivite LTM with L-glucose [75]. 
Is there any evidence that targeting the circuitry that drives motivation to consume rewarding 
food in a behaviorally relevant context actually effects feeding? It has been shown that during 
the proximal and distal aspects of feeding that there are changes in ventral striatal dopamine 
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levels. Cues associated with food elicit a robust increase in ventral striatal dopamine release 
[76] and cue-induced operant behaviors to obtain a food reward are reduced following 
microinjections of GABA receptor agonists into the VTA or dopamine receptor antagonists into 
the ventral striatum [77]. Similarly, sham-feeding corn oil which increases ventral striatal 
dopamine release [78] is decreased by dopamine receptor antagonists [79]. Intriguingly, 
intragastric administration of fat (which bypasses the oral cavity and is thus purely post-
ingestive) is associated with reduced ventral striatal dopamine [25]. Therefore it would appear 
that unlike the appetitive and consummatory phases of feeding, the urge to consume energy 
dense food is decreased once it has been digested, which is in line with a purely motivational 
signal that is adjusted in response to changes in homeostatic state. 
 
Neuroendocrine regulation of food intake through the mesolimbic pathway 
Circulating factors, which signal the long-term and short-term energy status of an organism, 
interact with the hypothalamus to regulate food intake and energy expenditure. A number of 
these factors also interact with the mesolimbic system to regulate hedonic feeding (Figure 1A). 
For instance, in rats, microinjection of the gastrointestinal orexigenic peptide ghrelin into either 
the VTA or NAc increases lever pressing to obtain a food reward [16]. Ghrelin increases the 
activity of dopaminergic VTA neurons in vitro [17] and systemic administration of ghrelin 
increases tonic dopamine release in the NAc shell (but not the core) of the ventral striatum [18]. 
Interestingly, the effect of microinjection of ghrelin into the VTA on food intake of laboratory 
chow is preserved, but its effect on operant behaviors to obtain a food reward is abolished when 
a dopamine receptor antagonist is microinjected into the ventral striatum [19]. These findings are 
consistent with previous observations that elevations in ventral striatal dopamine positively 
reinforces actions to obtain food, but not of food consumption itself [20]. 
 
Glucagon like peptide (GLP)-1 is an anorexigenic gut hormone released postprandially from the 
distal small intestine in proportion to the calorie intake of a meal. Microinjection of the GLP-1 
receptor (GLP-1R) agonist exendin (Ex)-4 into the VTA and NAc suppresses feeding [21], while 
microinjection of the GLP-1R antagonist Ex-9 into the NAc increases feeding [22]. In the 
context of hedonic feeding and in direct contrast to ghrelin, lever pressing to obtain a food 
reward following microinjection of Ex-4 into the VTA and NAc is decreased [21]. Although 
GLP-1R activation in the VTA and ventral striatum has marked effects on hedonic feeding, it 
does not result in changes in phasic dopamine release, at least in the NAc core of the ventral 
striatum [23]. Instead, GLP-1R activation in presynaptic glutamatergic neurons causes increased 
glutamate release and activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) subtype glutamate receptors in postsynaptic medium spiny neurons of the ventral 
striatum, to decrease food intake [23]. 
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Neuroendocrine regulation of food intake through the nigrostriatal pathway 
The crucial role of dorsal striatal dopamine in feeding is well established. Early studies revealed 
that nigrostriatal (as opposed to mesolimbic) lesions result in severe aphagia [10], and in mutant 
dopamine deficient aphagic mice who lack tyrosine hydroxylase (TH), the rate-limiting enzyme 
involved in dopamine production, virally mediated gene transfer of TH into the dorsal striatum 
(as opposed to the ventral striatum) is sufficient to rescue feeding [24]. These findings suggest 
that dorsal striatal dopamine functions in a similar fashion to ventral striatal dopamine to affect 
food intake. However, more recent evidence implicates dorsal striatal dopamine in the 
suppression of hedonic food intake by acting as a reward receipt signal. For instance, 
consumption of palatable food in lean humans causes dopamine release in the dorsal striatum, as 
revealed by positron emission tomography (PET)–magnetic resonance imaging (MRI), which is 
in close correlation to self-reported food pleasantness [11]. In mice, intragastric delivery of fat 
leads to tonic dopamine release in the dorsal striatum [25]. Interestingly, mice adjust the volume 
of fat ingested according to concentration, which itself is in direct proportion to tonic dopamine 
release [25]. These data suggest that dorsal striatal dopamine acts as a homeostatic signal to 
maintain constant levels of fat ingestion. The reasons for the discrepancy between the lesion and 
molecular studies and the dopamine measurement studies are presently unclear, but may be due 
to motor deficits in pharmacologically lesioned animals and developmental compensation in 
transgenic animals. 
 
There are reports of diminished dorsal striatal function in response to high fat food intake in 
obesity as adjudged by human functional MRI studies [26]. These data suggest that obesity is 
associated with reduced sensitivity to food reward receipt (mostly in the form of fat), likely 
caused by dysfunction of dorsal striatal dopamine signaling, which may lead individuals to 
compensate for by overindulgence of high-fat (HF) foods (Figure 1B). This raises the question, if 
dorsal striatal dopamine is restored in obese individuals, would this lead to a restoration of HF 
food reward receipt facilitating body weight loss? Indeed, in chronically HF-fed mice that have 
diminished dorsal striatal dopamine release, systemic administration of the lipid signaling 
molecule oleoylethanolamide (OEA) resulted in reduced HF food intake and body weight loss, 
with an associated elevation of dorsal striatal dopamine [27]. The effect of OEA on dorsal striatal 
dopamine was not seen in vagotomized mice, or in mice lacking the peroxisome proliferator 
receptor (PPAR)α, of which OEA is a natural ligand. Crucially, the suppression of HF food 
intake in response to OEA was abolished when a mixed dopamine receptor antagonist was 
microinjected into the dorsal striatum. Dorsal striatal dopamine signaling, thus, can be 
considered as a central sensor or ‘counter’ of ingested calories (in the form of fat at least) 
providing negative feedback due to reward receipt, much like the nutrient-sensing mechanisms in 
the hypothalamus that lead to satiation [28] (Figure 1A). A conserved role for dopamine in 
nutrient selection is suggested by studies performed on Drosophila, which reject diets low in 
essential amino acids due to dopamine neuron nutrient sensing [29]. 
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As mentioned above, the nigrostriatal pathway plays dual roles in motor and reward function. 
Obese individuals are more likely to develop Parkinson's disease (PD) and obese mice are more 
prone to nigrostriatal neurodegeneration and loss of dorsal striatal dopamine [30]. In a preclinical 
model of early stage PD, rats with partial lesions to the nigrostriatal pathway treated with Ex-4 
show restoration of dorsal striatal dopamine release [31]. It is conceivable thus that GLP-1 
interacts with the nigrostriatal dopamine pathway to also regulate hedonic feeding in obesity. 
 
How dieting may affect the mesolimbic pathway to regulate hedonic feeding 
Chronic food restriction results in changes in some of the peripheral factors described above 
which could potentially affect mesolimbic signaling and promote weight regain through 
increased hedonic feeding (Figure 1C). For instance, in mice, food restriction results in increased 
circulating ghrelin levels and weight regain is attenuated in ghrelin knockout (KO) animals under 
free refeeding conditions [32]. This effect is only observed on an HF diet (HFD) and not on 
standard chow [32]. In stress-induced hyperghrelinemic mice, the increased rewarding effect of 
HF foods are absent in ghrelin receptor KOs and is restored when the receptor is re-expressed in 
TH-containing neurons in the VTA [33]. Together, these observations further implicate a role for 
mesolimbic dopamine signaling in ghrelin induced hedonic feeding and weight gain. 
 
The circulating levels of the stress hormone corticosterone also increase following both an acute 
fast and chronic food restriction [33]. Microinjection of corticosterone into the VTA increases 
tonic dopamine release in the ventral striatum and systemic corticosterone increases palatable 
food intake [33], thus implicating an important role of the hypothalamic-pituitary-adrenal (HPA) 
axis activation in hedonic feeding and very likely postdieting weight regain as well. 
 
RYGB alters the hedonic value of high fat food 
Studies on humans and rodent models have consistently shown that RYGB promotes switching 
of preference from energy-dense foods to healthier alternatives, with patients stating that they 
prefer consumption of fruits and vegetables and actively avoid fatty foods [34]. In this context, in 
patients, consumption of low-fat foods is higher than that of HF foods post-surgery [35], and 
craving for energy-dense foods, particularly those high in fat content, is reduced [36]. Brief 
access lick tests reveal that RYGB-operated rats have a preference for lower concentrations of 
corn oil solution over higher ones [37] and in 24-h two bottle preference tests, RYGB rats prefer 
low over high concentrations of an Intralipid fat emulsion [38]. Also, in chronic feeding studies, 
RYGB rats have a lower preference for HFD over laboratory chow when presented with both 
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diets simultaneously [37]. Together, these observations suggest that RYGB modifies the hedonic 
value of fat via both pre- and postingestive processes. 
 
It cannot be overlooked that a learned aversion to HF foods develops after gastric bypass 
surgery. Few studies have been candid about the fact that patients often report severe discomfort 
in response to consuming high fat meals, sometimes even associated with a dumping syndrome 
[39]. In keeping with this, in rats after RYGB, oral gavage of corn oil induces a conditioned taste 
aversion [38] and meal-induced neuronal activity in the area postrema, a region implicated in the 
development of visceral illness, is increased [40]. Therefore, learned aversion might be a 
contributor to reduced HF food intake after surgery. Nevertheless, independent changes in 
reward processing in the striatum might also take place in response to calorie-rich foods, 
particularly those high in fat content. 
 
Evidence that RYGB surgery effects striatal dopamine signaling 
Given the documented effects of RYGB on the reward value of food, interest has grown in 
assessing potential modifications in striatal processing. PET studies with radiolabelled raclopride 
and fallypride, which are both selective D2/D3R antagonists, have provided conflicting results, 
with reports of an increase [41] and a decrease [42] in dorsal striatal D2/D3R availability 
respectively at 6 weeks after RYGB on morbidly obese (average BMI ∼45) women. A single-
photon emission computed tomography (SPECT) study with radiolabeled iodobenzamide, 
another selective D2/D3R antagonist, showed no changes in dorsal striatal D2/D3R availability 
again at 6 weeks after RYGB on morbidly obese (average BMI ∼45) women [43]. 
 
A significant limitation of these studies is that they neither provided a distinction between 
receptor expression levels and endogenous dopamine levels [44], nor a quantitative measure of 
feeding-induced changes in striatal dopamine release [11] after surgery. One way to assess this 
would be to use the preclinical models of RYGB in rodents and to determine feeding-induced 
extracellular tonic or phasic dopamine levels in the striatum after surgery-induced weight loss 
through the use of in vivo microdialysis or fast scan cyclic voltammetry respectively. Although 
no such studies have been performed to date, it was shown recently that dopamine levels were 
increased, ex vivo, in the dorsal striatum of RYGB-operated mice, compared to obese sham-
operated controls [45]. Despite the lack of information on changes in dopamine levels according 
to feeding state, these preliminary results suggest that RYGB might restore dorsal striatal 
dopamine function (Figure 1D). Future studies on the effect surgery has on ventral striatal 
dopamine, are warranted (Box 4). 
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How RYGB may affect the mesolimbic and nigrostriatal pathways to regulate hedonic 
feeding 
RYGB results in signature changes in some of the peripheral factors described above (Box 3). In 
contrast to calorie restriction however, the resulting profile may affect mesolimbic and 
nigrostriatal signaling in such a way as to promote weight loss maintenance through decreased 
hedonic feeding (Figure 1D). Indeed, some obesity treatments are thought to target the 
mesolimbic pathway to exert their effects on body weight [33]. The circulating levels of the 
anorexigenic gut hormones GLP-1 and peptide tyrosine tyrosine (PYY) increase following 
RYGB in both rodent and human studies 46 and 47, whereas circulating ghrelin levels decrease 
in rodent and most (but not all) human studies 46 and 47. Interestingly, unlike for animals, which 
lose weight after chronic food restriction, circulating corticosterone levels remain low after 
RYGB in rats [48]. 
 
Box 3.  
Long-term mediators of energy balance, RYGB surgery and the mesolimbic pathway 
Leptin released from adipose tissue and insulin from pancreas, are the two circulating hormones 
signaling long-term energy stores to the brain. Both have recently been implicated in regulating 
hedonic feeding by interacting with their cognate receptors in neurons of the mesolimbic 
pathway. Viral mediated knockdown of the leptin receptor in the VTA leads to increased 
preference for sucrose and HF foods [69]. Leptin decreases the activity of VTA neurons in vivo 
and in vitro [69] and central administration decreases ventral striatal tonic dopamine release in 
vivo [70]. Similarly, microinjection of insulin into the VTA decreases sucrose and HF food 
intake [72], and in brain slices, insulin has a long-term depressive effect on excitatory 
glutamatergic transmission in the VTA. This effect is occluded when animals eat a high-calorie 
meal, which causes insulin release and supports the notion that insulin causes the same plastic 
changes in VTA neurons in vivo [71]. The impact of insulin on dopamine release in the ventral 
striatum is not known and requires further investigation. However, these results suggest that 
both insulin and leptin decrease VTA neuronal activity and dopamine release in the ventral 
striatum to decrease the reward value of high sugar/fat foods. In obesity, circulating levels of 
leptin and insulin are elevated, together with resistance to receptor-mediated signaling. One may 
hypothesize then that leptin/insulin resistance could result in elevated ventral striatal dopamine 
release, contributing to increased hedonic feeding. 
RYGB and weight loss both restore sensitivity to leptin and insulin. Recent evidence suggests 
that it is unlikely that restored leptin signaling plays a critical role in the early weight loss after 
surgery. Indeed, RYGB fatty Zucker rats that lack a functional leptin receptor exhibit the initial 
weight loss [80]. However, leptin might be required for weight loss maintenance at the later 
stages after RYGB, as leptin-deficient ob/ob mice eventually regain weight after the procedure 
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[73]. The role of insulin signaling on RYGB-mediated weight loss has yet to be determined and 
cannot be ruled out. By extension, both leptin and insulin could exert their effects on hedonic 
feeding and bodyweight maintenance after RYGB via dampening the activity of the mesolimbic 
dopaminergic pathway. 
 
Box 4.  
Outstanding questions 
• Does RYGB modify/restore dopamine release in the ventral/dorsal striatum? Would these 
effects of RYGB extend to different sub-regions within the ventral/dorsal striatum? 
• How would RYGB affect dopamine release in other brain regions such as the prefrontal 
cortex? 
• Do the different bariatric surgical procedures differ in how they affect striatal dopamine 
signaling? 
• Would changes in dorsal striatal dopamine signaling after RYGB break negative feeding habits 
observed in obesity? 
• Would changes in striatal dopamine signaling after RYGB cause changes in hedonic feeding 
and bodyweight? 
• Which gut factors could provide a link between rerouted nutrient passage in the gut and 
modified striatal dopamine signaling after RYGB? Would different factors be involved with 
different nutrients thereby causing different effects on striatal dopamine release? 
• How would knowledge of changes in gut-dopamine signaling after RYGB in preclinical models 
apply to human patients and could this lead to novel treatment strategies for obesity? 
 
Although GLP-1 and PYY have been considered the prime candidates driving changes in feeding 
and bodyweight after RYGB surgery, contradictory results have been obtained from recent 
pharmacological and KO studies in rodents. Chronic central infusion of a neuropeptide Y2 
receptor (Y2-R) antagonist did not affect the surgery phenotype in rats with regards to feeding 
and body weight [49], and GLP-1R KO mice lose as much weight after RYGB as wild-type 
mice, and show no differences in food preference tests [49]. As unexpected as these results may 
be, the role of these hormones in RYGB driven weight loss and their interaction with the 
mesolimbic and nigrostriatal pathways ought not to be dismissed. For instance, GLP-2 receptor 
(GLP-2R) signaling could compensate for the deleted GLP-1R gene in KO mice. Also, gastric 
distension stimulates a population of hindbrain NTS neurons that express GLP-1 [50], which has 
been shown to project to the VTA and NAc [51]. Considering the reduced size of the gastric 
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pouch after surgery, the role of GLP-1 as a neuropeptide as opposed to a hormone in suppressing 
feeding may be more plausible, especially given the short half-life of GLP-1. Selective ablation 
of GLP-1R-expressing neurons in the mesolimbic pathway using GLP-1 conjugated to the 
neurotoxin saporin may provide key answers [52]. 
 
In the case of PYY, peripheral rather than central Y2-Rs may play a more prominent role in 
surgery-induced feeding suppression. In support of this, a study utilizing a rat model of relapse 
onto HF food following chronic food restriction, showed that HF-pellet- and cue-induced 
reinstatement of lever pressing for HF food were both abolished by systemic PYY 
administration, with the former effect being reversed by systemic, but not intra ARC Y2-R 
antagonist administration [53]. It is noteworthy that vagal afferents are stimulated by PYY [54], 
which has been shown to result in decreased VTA neuronal activity [55] and dopamine turnover 
in the ventral striatum [56]. Although it is hard to extrapolate rodent findings to human 
physiology, these results raise the question, are patients, after RYGB surgery, less susceptible to 
relapse to hedonic feeding because of elevated post-surgery levels of PYY negatively regulating 
the mesolimbic dopaminergic pathway? 
 
Another peripheral candidate affecting the mesolimbic dopaminergic pathway is the pancreatic 
hormone amylin, whose circulating concentration is increased after surgery in rats [46]. The 
amylin receptor complex is expressed in the VTA and ventral striatum and microinjection of the 
receptor agonist or antagonist into the VTA decreases and increases food intake respectively 
[57]. Intra-VTA amylin receptor agonist treatment also decreases lever pressing for a sucrose 
reward [57]. A subsequent study revealed that microinjection of amylin into the VTA reduces 
phasic dopamine release in the NAc core and knockdown of the amylin receptor in the VTA 
increases body weight on an HFD [58]. These results suggest that amylin physiologically 
suppresses hedonic feeding to regulate energy homeostasis, in rats. 
 
A highly interesting metabolic candidate that might affect the nigrostriatal pathway after surgery 
is OEA. OEA synthesis in the duodenum and jejunum peaks within half an hour of consuming a 
meal and is specifically increased by intragastric delivery of dietary lipids [59]. Intestinal OEA 
synthesis decreases with chronic consumption of an HFD, even in the absence of obesity [59]. 
Although not currently known, RYGB may restore OEA levels in the remaining gut (distal 
jejunum/proximal ileum) by rerouting nutrient (fat) passage to ultimately restore dorsal striatal 
dopamine and decrease fat intake. Similar to RYGB, OEA changes the preference for HF food to 
low fat food [27]. Also, the effects of RYGB and OEA on weight loss are dependent on intact 
vagal afferent signaling 27 and 60. 
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A potential role for intestinal fatty acid oxidation (FAO) in RYGB-induced weight loss also 
merits discussion. Pharmacological inhibitors of FAO have long been known to stimulate HF 
feeding, whereas stimulation of intestinal FAO suppresses feeding [61]. Consistent with this, 
both OEA and synthetic PPARα agonists that suppress appetite, increase the expression of 
enzymes involved in FAO in the gut and FAO products such as the ketone body β 
hydroxybutyrate (BHB) in the portal vein 62 and 63. As fatty acids also serve as natural ligands 
of PPARα [64], the increased fat accessing the distal gut after surgery could therefore ultimately 
result in increased intestinal FAO generating increased BHB and suppression of HF food intake. 
In support of this hypothesis, a priming effect of OEA has been observed as administration alone 
does not elicit dorsal striatal dopamine release, and fat must also be subsequently delivered to the 
gut for its full effects [27]. Therefore, RYGB may increase OEA and/or intestinal FAO to 
modify the reward value of fat. 
 
Concluding remarks and future research perspectives 
Progress has steadily been made in identifying brain systems involved in the hedonic effects of 
energy dense food and the adaptations that occur in response to their overconsumption and the 
ensuing weight gain. We have summarized evidence suggesting that the mesolimbic and 
nigrostriatal dopamine pathways play distinct roles in hedonic feeding. The radically different 
outcomes of RYGB and dieting on the hedonic value of high calorie (particularly HF) food and 
weight loss maintenance is possibly due, in part, to differential regulation of these pathways. The 
unique ability of RYGB to cause a profound and enduring change in our relation with food is 
likely a result of modifications to homeostatic, hedonic, and aversive systems in the CNS. 
 
Further insight into how the altered profile of peripheral factors in combination interact with the 
CNS to cause and maintain weight loss after bariatric surgery will undoubtedly aid in the 
development of novel anti-obesity therapies. Molecules such as OEA and GLP-1, which engage 
the hypothalamus and the striatum to decrease food intake and hedonic feeding, respectively, 
represent promising pharmaceutical candidates, as they will allow for a dual-pronged approach 
for treating obesity. 
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